Hepatitis C News

The FDA has issued a warning letter to an online pharmacy for allegedly selling unapproved and misbranded drugs, including hydroxychloroquine and chloroquine, for the treatment of COVID-19, lupus, rheumatoid arthritis and other diseases.

With the availability of simple and effective treatment for hepatitis C, specialists are seeking to expand the base of clinicians caring for patients with HCV by exploring new models of care.

It has been well over year since the COVID-19 pandemic began, and all aspects of health care have been impacted in various ways.

These reports include new research on the impact of screening methods, elimination efforts and direct-acting antiviral agents.

Despite having better liver function at diagnosis, Black patients with hepatitis C virus tended to have more aggressive hepatocellular carcinoma tumors compared with other racial groups, according to a study published in Cancer.

Although researchers observed a declining discard rate for kidneys from hepatitis C virus viremic donors over time, organs in 2019 were still 48% more likely to be discarded than those from aviremic seronegative donors.

A positive STI test may indicate a higher risk for hepatitis C virus reinfection among patients with HIV being treated with direct-acting antivirals, study findings published in Open Forum Infectious Diseases suggest.

Healio Gastroenterology presents the following reports on the most recent research in hepatology.

A combination of inreach and mailed outreach was an effective hepatitis C screening strategy among hard-to-reach populations, according to study results.

Hepatitis C testing uptake was high and treatment outcomes were good among patients seen at a homeless outreach service in a primary care center in London, according to a study presented at The Liver Meeting Digital Experience.